Yes, Restoril (temazepam) is a benzodiazepine. It is specifically classified as a benzodiazepine hypnotic agent, meaning it belongs to the subgroup of benzodiazepines designed primarily to promote sleep. The FDA approved it for the short-term treatment of insomnia, generally 7 to 10 days of use.
How Restoril Works in the Brain
Like all benzodiazepines, Restoril works by amplifying the effects of a natural brain chemical called GABA, which slows down nerve activity. When Restoril binds to specific receptor sites in the brain, it causes nerve cells to become less excitable by allowing more chloride ions to flow into them. This quiets neural activity across the brain, producing drowsiness, muscle relaxation, reduced anxiety, and ultimately sleep.
Restoril has a particular affinity for one type of receptor subunit (called alpha-1) that is closely tied to sedation. This selectivity is part of why it was developed and marketed specifically as a sleep medication rather than as an anti-anxiety drug, even though it shares the same basic mechanism as benzodiazepines like diazepam (Valium) or alprazolam (Xanax).
What Restoril Is Prescribed For
Restoril is approved only for short-term insomnia treatment in adults. The FDA label is explicit: it should be used for 7 to 10 days. The clinical trials that supported its approval lasted just two weeks, and the label states that safety and effectiveness beyond that timeframe are unknown.
This short treatment window distinguishes Restoril from some other sleep medications that are approved for longer use. If you’ve been taking it for more than a couple of weeks, that’s worth a conversation with your prescriber about whether a different approach makes sense.
How It Compares to Other Sleep Medications
Restoril is sometimes compared to non-benzodiazepine sleep aids like zolpidem (Ambien). While both help with sleep, they don’t perform identically. In a study comparing temazepam 15 mg to zolpidem 10 mg for transient insomnia, neither drug significantly reduced the time it took to fall asleep compared to placebo. However, zolpidem was better at reducing nighttime awakenings and time spent awake after initially falling asleep, while temazepam did not improve those measures. Zolpidem also scored higher on subjective ratings of sleep quality in that study.
This suggests that Restoril may not be the strongest option for people whose main complaint is waking up repeatedly during the night, though individual responses vary.
Its Legal Classification
The DEA classifies temazepam as a Schedule IV controlled substance, meaning it has a recognized potential for abuse, though lower than drugs in Schedules I through III. This is the same schedule as most other benzodiazepines. In practical terms, your pharmacy will track your prescription, and your prescriber may limit the number of refills.
Common Side Effects
The most frequently reported side effects are what you’d expect from a sedative: drowsiness that carries into the next day, dizziness, and a feeling of sluggishness. Older adults are more likely to experience pronounced versions of these effects, including confusion, unsteadiness, and a higher risk of falls.
Less common side effects include nervousness, mood changes, and an unusual sense of euphoria. Rare reactions can be more striking: memory problems, nightmares, hallucinations, uncontrolled eye movements, and paradoxical reactions where the drug causes excitement or restlessness instead of calm. These paradoxical effects are uncommon but can be alarming if you don’t know they’re a possibility.
Dependence and Withdrawal
Physical dependence can develop with regular benzodiazepine use, and Restoril is no exception. The withdrawal syndrome from benzodiazepines typically includes sleep disturbance, irritability, increased anxiety, panic attacks, hand tremor, sweating, difficulty concentrating, nausea, palpitations, headache, and muscle pain and stiffness. Some people also experience perceptual changes, like heightened sensitivity to light or sound.
The timeline depends partly on how long the drug stays in your system. The most common pattern is a short-lived “rebound” of anxiety and insomnia that appears within 1 to 4 days after stopping. A full withdrawal syndrome, when it occurs, typically lasts 10 to 14 days. In some cases, a third pattern emerges where anxiety symptoms return and persist, which can be difficult to distinguish from the original insomnia or anxiety coming back.
More serious withdrawal complications like seizures and psychotic reactions have been reported, primarily in people who were taking high doses. Stopping abruptly after regular use is risky. Tapering gradually under medical guidance is the standard approach.
Key Risks to Know About
Combining Restoril with opioids or other drugs that depress the central nervous system (alcohol, other sedatives, certain antihistamines) significantly increases the risk of dangerous sedation, slowed breathing, and death. The FDA label carries a boxed warning about this interaction, which is the most serious safety alert the agency issues.
Because benzodiazepines relax muscles and suppress respiratory drive, people with breathing-related sleep disorders like sleep apnea should be especially cautious. The drug can worsen the very breathing pauses that disrupt sleep in those conditions, creating a dangerous cycle.
Older adults face a compounded risk: they’re more sensitive to the sedative effects, more prone to falls from dizziness and unsteadiness, and more likely to experience confusion. For these reasons, many geriatric prescribing guidelines recommend avoiding benzodiazepines like Restoril in older populations when alternatives exist.